GlassScriptPhysician profile
David H Rosenbaum
NPI 1568596195
$39,072.96
in general payments reported to CMS, 2019-2025
41 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $2,284 · 2021: $6,145 · 2022: $19K · 2023: $6,385 · 2024: $2,365 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,899 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,979 · Education: $68.00 · Travel and Lodging: $18.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,898.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,979.00 |
| Education | $68.00 |
| Travel and Lodging | $18.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $21,814.54 | 2019-2024 | Aquabeam Robotic System, Aquabeam System |
| Medtronic, INC. | $9,382.32 | 2021-2025 | Interstim, Pipeline, Altaviva |
| Medtronic USA, INC. | $1,010.69 | 2019-2020 | |
| Teleflex LLC | $884.41 | 2020-2024 | Urolift |
| Atricure, INC. | $851.42 | 2021-2022 | |
| Boston Scientific Corporation | $833.36 | 2019-2025 | Lithovue, General - Therapies |
| Janssen Biotech, INC. | $770.51 | 2022-2025 | Erleada |
| Sumitomo Pharma America, INC. | $364.18 | 2023-2025 | Orgovyx, Gemtesa |
| Novartis Pharmaceuticals Corporation | $263.44 | 2022-2025 | |
| Urogen Pharma, INC. | $240.56 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $240.37 | 2020-2024 | Prolaris |
| Accord Healthcare, INC. | $236.11 | 2022-2025 | |
| Axonics, INC. | $198.40 | 2021 | |
| Astellas Pharma US INC | $178.77 | 2020-2025 | Xtandi |
| Pfizer INC. | $165.42 | 2023-2024 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,770.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rosenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.